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Background: Solitary fibrous tumor (SFT) is a rare fibroblastic mesenchymal tumor. It can originate from 
abdominal soft tissue which is extremely scarce, and liver indeed is super scant site. SFT liver (SFTL) is 
mostly benign, but it can be malignant and aggressive with metastases and a potential of recurrence. 
Hypoglycemia is the least reported feature which is resistant to medical management and will be resolved 
following resection of a SFT of liver. 
Case Report: A 67-year-old man presented with episodes of sudden onset loss of consciousness since 3 months 
before first visit. He was a previously healthy farmer, without any other complaint or past medical history except 
for episodes of sever hypoglycemia. Laboratory testing revealed hypoglycemia which was temporarily response to 
glucose infusion, hypoglycemia was refractive, and whole physical examination and laboratory tests were done 
and there were no abnormal findings. With probability of finding something such as insulinoma or any other 
tumor that secreted insulin or insulin-like growth factors, a magnetic resonance imaging (MRI) was performed and 
revealed an enhancing giant round and well-defined lesion in left lobe of live. 
Conclusions: We here present the first case of malignant SFTL presenting with hypoglycemia and metastasis 
to soft tissue as inguinal bulging 2 months after resection of liver mass, but this particular type of tumor needs 
more evaluation and investigation. 
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Introduction 
One of the less discussed entities of neoplasms is 
mesenchymal neoplasms, and solitary fibrous tumor 
(SFT) is an extremely rare subgroup of mesenchymal 
neoplasms. Back in the history, SFT was first 
differentiated from mesothelioma by Klemperer and 
Rabin in 1931. Many different names (solely 
hemangiopericytoma) have been used for the 
description of this neoplasm. SFT can be seen in every 
anatomic site but the most common site reported is the 
SFT of the pleura. Despite serosal site, it can originate 
from abdominal soft tissue which is extremely scarce, 
and liver indeed is super scant site, and cases reported 
in literature is < 50 (mostly benign) until the present 
day and data about SFT’s malignant potential, invasive 
growth and natural history are not well grounded. 
When it comes to diagnosis, it is challenging in terms 
of pre-operative and even post-operative diagnosis. It is 
important to exclude other differential diagnosis such as 
hepatocellular carcinoma, GIST, leiomyoma, and 
sarcoma. There is a 2:1 female-to-male predominance 
with the ages of affected individuals ranging from 27 to 
83 years (1) imaging is helpful, but it cannot distinguish 
between malignant and benign tumors. Most often, SFT 
liver (SFTL) is a solitary encapsulated highly vascular 
tumor showing heterogeneous enhancement in 
computerized tomography scans. Diagnosis cannot be 
certainly obtained based on clinical and radiographic 
features, and histopathological sampling and 
immunohistochemistry are the main tools to establish a 
definite diagnosis (2). Given the limited number of cases 
reported in literature, it is difficult to establish the long-
term prognosis for the patient. Progressively local growth 
is to be expected. The ability of this tumor to grow to 
large sizes should prompt strong consideration for 
resection at the time of diagnosis (2). 
The symptoms vary from a totally asymptomatic 
patient to common symptoms such as abdominal pain 
and cholestasis (due to compression of biliary duct), 
and most infrequently patient can present with 
hypoglycemia due to secretion of insulin-like growth 
factors (3). Surgery is the treatment of choice. 
Performing resection with a 1 cm margin, free margins 
should always be achieved, and in cases where a 
positive margin is found in the post-operative period, 
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re-resection is indicated (4). At present, no role exists 
for adjuvant medical therapy for this disease. The role 
of chemotherapy and radiotherapy in these tumors is 
still controversial and is reserved for cases when 
resection is incomplete, or there are signs of 
malignancy (5). There is no solid association between 
histopathologic finding and SFT behavior which make 
this tumor even more challenging for every physician. 
Despite adequate local control, estimated recurrence 
rates for malignant SFTs are around 30% (34-36%). 
Locoregional recurrent disease has been shown to be 
more common in patients with malignant histologic 
features compared with those with typical histology. 
While small tumors with low mitotic rates are highly 
unlikely to metastasize, large tumors ≤ 15 cm, which 
occur in patients ≤ 55 years, with mitotic figures ≤ 4/10 
high-power fields require close follow-up and have a 
high risk of both metastasis and death (6). The small 
number of patients with a SFT of the liver and its 
unknown and unpredictable natural behavior creates 
the need to a careful registration and follow-up of all 
identified cases. We presented here the first SFTL 
presenting refractory hypoglycemia with metastasis in 
soft tissue which is unrivaled in literature. 
 
Case Report 
A 67-year-old male presented with episodes of sudden 
onset loss of consciousness since 3 months before first 
visit, he was a previously healthy farmer, without any 
other complaint or past medical history except for 
episodes of sever hypoglycemia. Laboratory testing 
revealed hypoglycemia which was temporarily response 
to glucose infusion, hypoglycemia was refractive, and a 
whole physical examination and laboratory tests were 
done and there were no abnormal findings, with 
probability of finding something such as insulinoma or 
any other tumor that secret insulin or insulin-like growth 
factors, a magnetic resonance imaging (MRI) imaging 
was performed and revealed an enhancing giant round and 
well-defined lesion in left lobe of liver, with dimension of 
10 * 10 cm (Figures 1 and 2), pancreas was normal.  
 
 
Figure 1. Tumor magnetic resonance imaging originating 
from left lobe of liver with no local aggression 
The other parts of abdomen and pelvis and chest 
were normal. The patient underwent surgery under 
general anesthesia and laparotomy was done, in OR, an 
upper midline laparotomy has provided an excellent 
access to the abdomen. The abdomen was clean, no 
sign of ascites and no peritoneal lesion.  
 
 
Figure 2. Tumor magnetic resonance imaging -originating 
from left lobe of liver 
 
As expected, a huge round tumor originating from the 
left lobe of liver was found with a well-defined capsule 
and without invasion to the adjacent organs (Figure 3). 
The frozen section biopsy was done, and the report was a 
subgroup of sarcoma, left lobectomy of liver was done 
without subsequent problem in dissecting the lesion. The 
blood loss was about 600cc which compensated with 
transfusion. The hemostasis was achieved. The patient’s 
hypoglycemia was improved after surgery, and he was 
discharged a few days later. Interestingly, permanent 
pathology report was compatible with SFT of liver. In 
subsequent follow-up he was symptom free and had no 
problem, 8 months after surgery, he came back with a 
bulging mass in right inguinal hernia, incisional biopsy 
was done and reported synovial sarcoma and he had 
undergone another surgery again and the lesion was 
widely excised and sent for pathology, and the pathology 
report was SFT again, which probably metastasis of liver 
lesion. In 6 months follow-up after second surgery, he had 
no other problem. This presentation has never been 
reported previously in literature.  
 
 
Figure 3. Tumor gross anatomy -note the capsule 
An Unusual Giant Solitary Fibrous Tumor of the Liver 
 




Evaluating a patient presenting with recurrent 
hypoglycemia, SFT is the last to come to mind. SFT is 
a fibroblastic mesenchymal tumor originally described 
in the pleura (3). Extrathoracic SFTs have been 
described at almost every anatomic location of human 
body, but reports of SFT in the abdominal cavity are 
rare (7). Most extrathoracic SFTs appear to pursue a 
benign behavior (2). However, SFTL can be aggressive 
and malignant. Reports of malignant SFTL can be 
count on the fingers of hands. Most reported site of 
SFTL is left segment of the liver. Hepatic SFT is very 
rare, and surgery remains the mainstay of treatment (8). 
Hypoglycemia is the least reported feature which is 
resistant to medical management and will be resolved 
following resection of a SFT of liver and in this case 
metastases is concurrent with a recurrence of 
hypoglycemia. SFTs of the liver have a real risk of 
malignant transformation. The severity of the tumor-
associated hypoglycemia may parallel the tumor 
burden and activity. The syndrome is the systemic 
effect of IGF2 secreted by the tumor (9). Malignant 
SFTs involving the liver are currently treated by surgical 
resection, with the aim of obtaining a margin-negative 
specimen (10). Taking all together this report of malignant 
SFTL with only presentation as hypoglycemia, metastasis 
to soft tissue presenting as a bulging inguinal mass 
without concurrent hypoglycemia is unique, and he has 
not been reported previously. 
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